AR092595A1 - Compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- AR092595A1 AR092595A1 ARP130103326A ARP130103326A AR092595A1 AR 092595 A1 AR092595 A1 AR 092595A1 AR P130103326 A ARP130103326 A AR P130103326A AR P130103326 A ARP130103326 A AR P130103326A AR 092595 A1 AR092595 A1 AR 092595A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen
- cycloalkyl
- radicals
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 16
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- 229910052799 carbon Inorganic materials 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 7
- 150000002431 hydrogen Chemical class 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- MALIONKMKPITBV-UHFFFAOYSA-N 2-(3-chloro-4-hydroxyphenyl)-n-[2-(4-sulfamoylphenyl)ethyl]acetamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CCNC(=O)CC1=CC=C(O)C(Cl)=C1 MALIONKMKPITBV-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Estos compuestos, los N-óxidos, los tautómeros, las prodrogas y las sales farmacéuticamente aceptables de los mismos son inhibidores de la fosfodiesterasa de tipo 10A y su uso en la elaboración de un medicamento los vuelve adecuados para tratar o controlar los trastornos médicos seleccionados entre trastornos neurológicos y trastornos psiquiátricos, para aliviar los síntomas asociados con dichos trastornos y para reducir el riesgo de dicho trastornos. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque, en la fórmula (1), las variables X, Y, Q¹, Q², R¹ y R² tienen los siguientes significados: X es C-R³ o N; Q¹ es S u O y Q² es C-R⁴ o N y Q² está conectado a X a través de una unión doble mientras que Q¹ está conectado a X a través de una unión simple; o Q² es S u O y Q¹ es C-R⁴ o N y Q¹ está conectado a X a través de una unión doble mientras que Q² está conectado a X a través de una unión simple; Y es C-R⁵ o N; R¹ se selecciona entre el grupo que consiste en: hidrógeno, halógeno, ciano, nitro, R¹¹, OH, OR¹², S(O)qR¹³, C(O)H, C(O)R¹⁴, C(O)OH, C(O)OR¹⁵, OC(O)R¹⁶, Y¹-NR¹⁷R¹⁸, Y¹-N(R¹⁹)-Y³-NR¹⁷R¹⁸, Y¹-N(R¹⁹)-Y²-R¹⁵ᵃ y una unidad Z¹-Ar¹; R² se selecciona entre el grupo que consiste en: hidrógeno, halógeno, ciano, nitro, R²¹, OH, OR²², S(O)qR²³, C(O)H, C(O)R²⁴, C(O)OH, C(O)OR²⁵, OC(O)R²⁶, Y¹-NR²⁷R²⁸, Y¹-N(R²⁹)-Y³-NR²⁷R²⁸, Y¹-N(R¹⁹)-Y²-R²⁵ᵃ y una unidad Z²-Ar²; con la condición de que por lo menos uno de R¹ y R² debe ser diferente de hidrogeno; R³ se selecciona entre el grupo que consiste en: hidrógeno, halógeno, ciano, nitro, R³¹, OR³², S(O)qR³³, C(O)H, C(O)R³⁴, C(O)OH, C(O)OR³⁵, OC(O)R³⁶, Y¹-NR³⁷R³⁸, Y¹-N(R³⁹)-Y³-NR³⁷R³⁸, Y¹-N(R³⁹)-Y²-R³⁵ᵃ y una unidad Z³-Ar³; R⁴ se selecciona entre el grupo que consiste en: hidrógeno, halógeno, ciano, nitro, R⁴¹, OR⁴², S(O)qR⁴³, C(O)H, C(O)R⁴⁴, C(O)OH, C(O)OR⁴⁵, OC(O)R⁴⁶, Y¹-NR⁴⁷R⁴⁸, Y¹-N(R⁴⁹)-Y³-NR⁴⁷R⁴⁸, Y¹-N(R⁴⁹)-Y²-R⁴⁵ᵃ y una unidad Z⁴-Ar⁴; R⁵ se selecciona entre el grupo que consiste en: hidrógeno, halógeno, ciano, nitro, R⁵¹, OR⁵², S(O)qR⁵³, C(O)H, C(O)R⁵⁴, C(O)OH, C(O)OR⁵⁵, OC(O)R⁵⁶, Y¹-NR⁵⁷R⁵⁸, Y¹-N(R⁵⁹)-Y³-NR⁵⁷R⁵⁸, Y¹-N(R⁵⁹)-Y²-R⁵⁵ᵃ y una unidad Z⁵-Ar⁵; R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R³¹, R³², R³³, R³⁴, R³⁵, R³⁶, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁵¹, R⁵², R⁵³, R⁵⁴, R⁵⁵ y R⁵⁶, se seleccionan independientemente entre sí entre el grupo que consiste en: alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquenilo C₅₋₈, cicloalquil C₃₋₈-alquilo C₁₋₄, donde los 6 sustituyentes mencionados anteriormente pueden no estar sustituidos, pueden estar parcial o completamente halogenados o pueden portar 1, 2 ó 3 radicales Rʸ, y heterociclilo de entre 5 y 8 miembros unido a C, que está saturado o parcialmente insaturado y tiene 1 ó 2 unidades heteroatómicas como miembros del anillo, que se seleccionan entre el grupo que consiste en: O, N, S, S(O), S(O)₂ o N-Rˣ, donde el heterociclilo no está sustituido o porta 1, 2, 3 ó 4 radicales Rʸʸ; R¹⁷ y R¹⁸, se seleccionan independientemente entre sí entre el grupo que consiste en: hidrógeno, tri-alquil C₁₋₄sililo, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquenilo C₅₋₈, cicloalquil C₃₋₈-alquilo C₁₋₄, donde los 6 sustituyentes mencionados anteriormente pueden no estar sustituidos, pueden estar parcial o completamente halogenados o pueden portar 1, 2 ó 3 radicales Rʸ, alquil C₁₋₈carbonilo, haloalquil C₁₋₄carbonilo, alquil C₁₋₈sulfonilo, haloalquil C₁₋₄sulfonilo, y heterociclilo de entre 5 y 8 miembros unido a C, que está saturado o parcialmente insaturado y tiene 1 ó 2 unidades heteroatómicas como miembros del anillo, que se seleccionan entre el grupo que consiste en: O, N, S, S(O), S(O)₂ o N-Rˣ, donde el heterociclilo no está sustituido o porta 1, 2, 3 ó 4 radicales Rʸʸ o R¹⁷ y R¹⁸, junto con el átomo de nitrógeno al cual están unidos, forman un heterociclilo unido a N de entre 5 y 8 miembros, que está saturado, parcialmente insaturado o es aromático y además del átomo de nitrógeno puede tener 1 ó 2 unidades heteroatómicas adicionales como miembros del anillo, que se seleccionan entre el grupo que consiste en: O, N, S, S(O), S(O)₂ o N-Rˣ, donde el heterociclilo no está sustituido o porta 1, 2, 3 ó 4 radicales Rʸʸ; R¹⁹, R²⁹, R³⁹, R⁴⁹ y R⁵⁹, independientemente entre sí, son: hidrógeno o tienen uno de los significados que se adjudicó a R¹¹; R²⁷ y R²⁸ son como se definen para R¹⁷ y R¹⁸; R³⁷ y R³⁸ son como se definen para R¹⁷ y R¹⁸; R⁴⁷ y R⁴⁸ son como se definen para R¹⁷ y R¹⁸; R⁵⁷ y R⁵⁸ son como se definen para R¹⁷ y R¹⁸; R¹⁵ᵃ, R²⁵ᵃ, R³⁵ᵃ, R⁴⁵ᵃ y R⁵⁵ᵃ, independientemente entre sí, tienen uno de los significados que se adjudicó a R¹¹; q es 0, 1 ó 2; Ar¹, Ar², Ar³, Ar⁴ y Ar⁵, se seleccionan independientemente entre sí entre el grupo que consiste en: arilo, hetarilo monocíclico de 5 ó 6 miembros y hetarilo bicíclico de 9 ó 10 miembros, donde el hetarilo tiene 1, 2 ó 3 heteroátomos como miembros del anillo que se seleccionan entre O, S y N, donde el arilo y el hetarilo no están sustituidos o pueden portar 1, 2, 3 ó 4 sustituyentes RAʳ idénticos o diferentes; Y¹ es una unión simple, alquileno C₁₋₄, Y⁵-O-Y⁶, Y⁵-S(O)q-Y⁶, Y⁵-C(O)-Y⁶, Y⁵-C(S)-Y⁶, Y⁵-C(O)O-Y⁶, Y⁵-OC(O)-Y⁶, o Y⁵-N(Rᶻ)Y⁴; Y² es una unión simple, alquileno C₁₋₄, Y⁵-O-Y⁶, Y⁵-S(O)q-Y⁶, Y⁵-C(O)-Y⁶, Y⁵-C(S)-Y⁶, Y⁵-C(O)O-Y⁶, Y⁵-OC(O)-Y⁶, o Y⁵-N(Rᶻ)-Y⁴; Y³ es una unión simple, alquileno C₁₋₄, Y⁵-S(O)q-Y⁶, Y⁵-C(O)-Y⁶, Y⁵-C(S)-Y⁶, Y⁵-C(O)O-Y⁶, o Y⁵-OC(O)-Y⁶; Y⁴ es un alquileno C₁₋₄, Y⁵-S(O)q-Y⁶, Y⁵-C(O)-Y⁶, Y⁵-C(S)-Y⁶, Y⁵-C(O)O-Y⁶, o Y⁵-OC(O)-Y⁶; Y⁵ es una unión simple o alquileno C₁₋₄; Y⁶ es una unión simple o alquileno C₁₋₄; Z¹, Z², Z³, Z⁴ y Z⁵ se seleccionan independientemente entre sí entre: una unión simple, alquileno C₁₋₄, Y⁵-O-Y⁶, Y⁵-S(O)q-Y⁶, Y⁵-C(O)-Y⁶, Y⁵-C(S)-Y⁶, Y⁵-C(O)O-Y⁶, Y⁵-OC(O)-Y⁶ e Y⁵-N(Rᶻ)-Y⁴; Rˣ se selecciona entre el grupo que consiste en: hidrógeno, alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquenilo C₅₋₈, cicloalquil C₃₋₈-alquilo C₁₋₄, donde los 6 sustituyentes mencionados anteriormente pueden no estar sustituidos, pueden estar parcial o completamente halogenados o pueden portar 1, 2 ó 3 radicales Rʸ, fenilo y fenil-alquilo C₁₋₄, donde fenilo y fenil-alquilo C₁₋₄ no están sustituidos o pueden portar 1, 2, 3 ó 4 radicales Rʸʸ; Rʸ se selecciona entre el grupo que consiste en: ciano, OH, ORʸ², S(O)qRʸ³, C(O)H, C(O)Rʸ⁴, C(O)OH, C(O)ORʸ⁵, OC(O)Rʸ⁶, Y¹-NRʸ⁷Rʸ⁸, Y¹-N(Rʸ⁹)-Y³-NRʸ⁷Rʸ⁸ y Y¹-N(Rʸ⁹)-Y²-Rʸ⁰; Rʸʸ se selecciona entre el grupo que consiste en: ciano, halógeno, Rʸ¹, OH, ORʸ², S(O)qRʸ³, C(O)H, C(O)Rʸ⁴, C(O)OH, C(O)ORʸ⁵, OC(O)Rʸ⁶, Y¹-NRʸ⁷Rʸ⁸, Y¹-N(Rʸ⁹)-Y³-NRʸ⁷Rʸ⁸ y Y¹-N(Rʸ⁹)-Y²-Rʸ⁰; Rʸ⁰, Rʸ², Rʸ³, Rʸ⁴, Rʸ⁵ y Rʸ⁶, se seleccionan independientemente entre sí entre el grupo que consiste en: alquilo C₁₋₈, alquenilo C₂₋₈, alquinilo C₂₋₈, cicloalquilo C₃₋₈, cicloalquenilo C₅₋₈, cicloalquil C₃₋₈-alquilo C₁₋₄, y heterociclilo de entre 5 y 8 miembros unido a C, que está saturado o parcialmente insaturado y tiene 1 ó 2 unidades heteroatómicas c
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702005P | 2012-09-17 | 2012-09-17 | |
| US201261702371P | 2012-09-18 | 2012-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092595A1 true AR092595A1 (es) | 2015-04-29 |
Family
ID=49226152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103326A AR092595A1 (es) | 2012-09-17 | 2013-09-17 | Compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9388180B2 (es) |
| EP (1) | EP2895489B1 (es) |
| JP (1) | JP2015528484A (es) |
| KR (1) | KR20150056844A (es) |
| CN (1) | CN105102461A (es) |
| AR (1) | AR092595A1 (es) |
| AU (1) | AU2013314244A1 (es) |
| BR (1) | BR112015005935A2 (es) |
| CA (1) | CA2883910A1 (es) |
| HK (1) | HK1206728A1 (es) |
| IL (1) | IL237626A0 (es) |
| IN (1) | IN2015DN01900A (es) |
| MX (1) | MX2015003419A (es) |
| RU (1) | RU2015114331A (es) |
| SG (1) | SG11201502074YA (es) |
| TW (1) | TW201418264A (es) |
| UY (1) | UY35036A (es) |
| WO (1) | WO2014041175A1 (es) |
| ZA (1) | ZA201501458B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015535227A (ja) | 2012-10-26 | 2015-12-10 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｓｙｋの３，４−二置換１ｈ−ピラゾール及び４，５−二置換チアゾール阻害剤 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| KR20200140817A (ko) | 2018-03-02 | 2020-12-16 | 코디악 사이언시스 인코포레이티드 | Il-6 항체 그리고 이의 융합 작제물 및 접합체 |
| CN111592495A (zh) * | 2020-07-06 | 2020-08-28 | 上海启讯医药科技有限公司 | 一种2-正丁基-4-氯-5甲酰基咪唑的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| US7057042B2 (en) * | 2002-05-29 | 2006-06-06 | Abbott Laboratories | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction |
| WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| JP2008501776A (ja) | 2004-06-07 | 2008-01-24 | ファイザー・プロダクツ・インク | 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ１０の阻害 |
| US20060160814A1 (en) | 2004-09-03 | 2006-07-20 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| JP5046942B2 (ja) * | 2004-09-30 | 2012-10-10 | テイボテク・フアーマシユーチカルズ | Ｈｃｖ阻害性の二環式ピリミジン類 |
| EP1940819A1 (en) | 2005-08-16 | 2008-07-09 | Memory Pharmaceuticals Corporation | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| BRPI0707223A2 (pt) | 2006-01-27 | 2011-04-26 | Pfizer Prod Inc | compostos de derivados de aminoftalazina |
| JP2009527560A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| JP2009527562A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| EP1996587A1 (en) | 2006-02-23 | 2008-12-03 | Pfizer Products Incorporated | Substituted quinazolines as pde10 inhibitors |
| JP2009528365A (ja) | 2006-02-28 | 2009-08-06 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体 |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996574A1 (en) | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US8492394B2 (en) | 2006-07-10 | 2013-07-23 | H. Lundbeck A/S | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| RU2010126622A (ru) * | 2007-11-30 | 2012-01-10 | УАЙТ ЭлЭлСи (US) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 |
| WO2009070583A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| CA2706986A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| PE20110223A1 (es) | 2008-06-10 | 2011-05-07 | Abbvie Inc | DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA |
| WO2010054260A1 (en) * | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2011008597A1 (en) | 2009-07-14 | 2011-01-20 | Schering Corporation | Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors |
| US8361962B2 (en) | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
-
2013
- 2013-09-16 HK HK15107215.7A patent/HK1206728A1/xx unknown
- 2013-09-16 WO PCT/EP2013/069173 patent/WO2014041175A1/en not_active Ceased
- 2013-09-16 JP JP2015531593A patent/JP2015528484A/ja not_active Withdrawn
- 2013-09-16 CN CN201380048224.3A patent/CN105102461A/zh active Pending
- 2013-09-16 KR KR1020157009897A patent/KR20150056844A/ko not_active Withdrawn
- 2013-09-16 CA CA2883910A patent/CA2883910A1/en not_active Abandoned
- 2013-09-16 IN IN1900DEN2015 patent/IN2015DN01900A/en unknown
- 2013-09-16 AU AU2013314244A patent/AU2013314244A1/en not_active Abandoned
- 2013-09-16 MX MX2015003419A patent/MX2015003419A/es unknown
- 2013-09-16 SG SG11201502074YA patent/SG11201502074YA/en unknown
- 2013-09-16 BR BR112015005935A patent/BR112015005935A2/pt not_active IP Right Cessation
- 2013-09-16 RU RU2015114331A patent/RU2015114331A/ru not_active Application Discontinuation
- 2013-09-16 EP EP13765695.5A patent/EP2895489B1/en not_active Not-in-force
- 2013-09-17 UY UY0001035036A patent/UY35036A/es not_active Application Discontinuation
- 2013-09-17 US US14/029,142 patent/US9388180B2/en not_active Expired - Fee Related
- 2013-09-17 AR ARP130103326A patent/AR092595A1/es unknown
- 2013-09-17 TW TW102133710A patent/TW201418264A/zh unknown
-
2015
- 2015-03-03 ZA ZA2015/01458A patent/ZA201501458B/en unknown
- 2015-03-09 IL IL237626A patent/IL237626A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013314244A1 (en) | 2015-03-12 |
| US9388180B2 (en) | 2016-07-12 |
| EP2895489A1 (en) | 2015-07-22 |
| RU2015114331A (ru) | 2016-11-10 |
| HK1206728A1 (en) | 2016-01-15 |
| MX2015003419A (es) | 2015-09-23 |
| AU2013314244A8 (en) | 2015-04-30 |
| SG11201502074YA (en) | 2015-05-28 |
| CN105102461A (zh) | 2015-11-25 |
| EP2895489B1 (en) | 2017-10-18 |
| US20140107126A1 (en) | 2014-04-17 |
| IN2015DN01900A (es) | 2015-08-07 |
| IL237626A0 (en) | 2015-04-30 |
| KR20150056844A (ko) | 2015-05-27 |
| TW201418264A (zh) | 2014-05-16 |
| ZA201501458B (en) | 2018-11-28 |
| CA2883910A1 (en) | 2014-03-20 |
| BR112015005935A2 (pt) | 2017-07-04 |
| JP2015528484A (ja) | 2015-09-28 |
| WO2014041175A1 (en) | 2014-03-20 |
| UY35036A (es) | 2014-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
| AR114083A2 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
| AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
| AR098492A1 (es) | Derivados de purina | |
| AR106299A1 (es) | Compuestos de piridona y fungicidas agrícolas y hortícolas que contienen dichos compuestos como ingrediente activo | |
| AR113905A1 (es) | Feniléteres herbicidas | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR092595A1 (es) | Compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| AR091368A1 (es) | Compuestos y composiciones para modular la actividad de egfr | |
| AR084444A1 (es) | Oxindolpirimidinas bencilicas y las preparaciones farmaceuticas que las contienen | |
| AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR099937A1 (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR097435A1 (es) | 6-alquinilpiridinas | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR082850A1 (es) | Aminopirazoloquinazolinas | |
| CU20120099A7 (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| AR089996A1 (es) | Triterpenoides de c-3 cicloalquenilo con actividad inhibidora de la maduracion del hiv | |
| AR097436A1 (es) | Bis-amidopiridinas | |
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |